MDMegan Duster

Megan Duster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Megan Duster has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Nasia Safdar

    William S. Middleton Memorial Veterans Hospital, Madison, WI; Department of Medicine, University of Wisconsin-Madison, Madison, WI

    11 shared publications
  • Nasia Safdar

    University of Wisconsin, Madison, Wisconsin

    7 shared publications
  • Simone Warrack

    Division of Infectious Disease, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

    7 shared publications
  • Susan Valentine

    Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI

    5 shared publications
  • Anna Barker

    Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin – Madison, Madison, Wisconsin

    3 shared publications
  • Daniel Shirley

    Department of Medicine, School of Medicine and Public Health, University of Wisconsin at Madison, Madison, Wisconsin

    3 shared publications

Latest Publications

  • Open Access

    1147. Pseudo-Outbreak of Clostridium paraputrificum Related to Anaerobic Tent Contamination

    by Kaitlin Mitchell, Luann Rece, Megan Duster, Daniel Shirley, Nasia Safdar, Derrick Chen

    Background Over a 2-month period, eight patient cultures in our clinical microbiology laboratory were positive for Clostridium paraputrificum, an uncommon spore-forming microbe. The possibility of a pseudo-outbreak related to contamination in the laboratory’s anaerobic tent was considered. Methods This study occurred at a 505-bed tertiary care university-affiliated teaching hospital. Patient samples were cultured and evaluated following standard protocols, and isolates of C. paraputrificum were identified using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). To identify additional cases, MALDI-TOF MS testing reports were manually reviewed and matched to patient records. Concurrently, the laboratory’s anaerobic tent was sampled after cleaning with isopropyl alcohol (and later with bleach or sporicidal disinfectant) following standard procedures and protocols recommended by the tent manufacturer (Coy). Pulsed-field gel electrophoresis (PFGE) was performed on isolates from patients (n = 8) and the anaerobic tent (n = 6). Results Despite cleaning with isopropyl alcohol or bleach, surface samples from the anaerobic tent grew C. paraputrificum. PFGE analysis revealed all patient and anaerobic tent isolates to be indistinguishable, suggesting that they originated from a common source. Growth of the organism from patient samples was therefore regarded as potential contamination. Prior to this, six of the eight patients received antibiotics related to this positive culture and had Infectious Disease consultations. Providers of the patients were contacted regarding the contamination issue. The anaerobic tent manufacturer was consulted and ultimately recommended using Peridox Sporicidal Disinfectant. Six months later, the tent was re-sampled and did not yield positive cultures. Conclusion A pseudo-outbreak of the uncommon organism C. paraputrificum was related to insufficient disinfection practices of an anaerobic culture tent. This had negative effects on our institution and patient care in terms of cost, time, and unnecessary treatment. The use of sporicidal disinfectant has since proven effective to prevent contamination from spore-producing microbes. Disclosures All authors: No reported disclosures.

  • Open Access

    Wisconsin microbiome study, a cross-sectional investigation of dietary fibre, microbiome composition and antibiotic-resistant organisms: rationale and methods

    by Shoshannah Eggers, Kristen MC Malecki, Paul Peppard, Julie Mares, Daniel Shirley, Sanjay K Shukla, Keith Poulsen, Ronald Gangnon, Megan Duster, Ashley Kates, et al.

    Introduction: Prevention of multidrug-resistant organism (MDRO) infections, such as those caused by methicillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci, fluoroquinolone-resistant Gram-negative bacteria and Clostridium difficile is crucial. Evidence suggests that dietary fibre increases gut microbial diversity, which may help prevent colonisation and subsequent infection by MDROs. The aim of the Winning the War on Antibiotic Resistance (WARRIOR) project is to examine associations of dietary fibre consumption with the composition of the gut microbiota and gut colonisation by MDROs. The secondary purpose of the study is to create a biorepository of multiple body site specimens for future microbiota research. Methods and analysis: The WARRIOR project collects biological specimens, including nasal, oral and skin swabs and saliva and stool samples, along with extensive data on diet and MDRO risk factors, as an ancillary study of the Survey of the Health of Wisconsin (SHOW). The SHOW is a population-based health survey collecting data on several different health determinants and outcomes, as well as objective body measurements and biological specimens. WARRIOR participants include 600 randomly selected Wisconsin residents age 18 and over. Specimens are screened for MDRO colonisation and DNA is extracted for 16S ribosomal RNA-based microbiota sequencing. Data will be analysed to assess the relationship between dietary fibre, the gut microbiota composition and gut MDRO colonisation. Ethics and dissemination: The WARRIOR project is approved by the University of Wisconsin Institutional Review Board. The main results of this study will be published in a peer-reviewed scientific journal.


  • Open Access

    Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study

    by Shoshannah Eggers, Anna K. Barker, Susan Valentine, Timothy Hess, Megan Duster, Nasia Safdar

    Infection by Staphylococcus aureus (S. aureus) is a major cause of morbidity and mortality. Colonization by S. aureus increases the risk of infection. Little is known about decolonization strategies for S. aureus beyond antibiotics, however probiotics represent a promising alternative. A randomized controlled trial was conducted to determine the efficacy of Lactobacillus rhamnosus (L. rhamnosus) HN001 in reducing carriage of S. aureus at multiple body sites. One hundred thirteen subjects, positive for S. aureus carriage, were recruited from the William S. Middleton Memorial Medical Center, Madison, WI, USA, and randomized by initial site of colonization, either gastrointestinal (GI) or extra-GI, to 4-weeks of oral L. rhamnosus HN001 probiotic, or placebo. Nasal, oropharyngeal, and axillary/groin swabs were obtained, and serial blood and fecal samples were collected. Differences in prevalence of S. aureus carriage at the end of the 4-weeks of treatment were assessed. The probiotic and placebo groups were similar in age, gender, and health history at baseline. S. aureus colonization within the stool samples of the extra-GI group was 15% lower in the probiotic than placebo group at the endpoint of the trial. Those in the probiotic group compared to the placebo group had 73% reduced odds (OR 0.27, 95% CI 0.07–0.98) of methicillin-susceptible S. aureus presence, and 83% reduced odds (OR 0.17, 95% CI 0.04–0.73) of any S. aureus presence in the stool sample at endpoint. Use of daily oral L. rhamnosus HN001 reduced odds of carriage of S. aureus in the GI tract, however it did not eradicate S. aureus from other body sites. ClinicalTrials.gov Identifier: NCT01321606 . Registered March 21, 2011.


  • Open Access

    Intra-Facility Acquisition of Methicillin-Resistant Staphylococcus aureus (MRSA) in Southern Wisconsin Skilled Nursing Facilities

    by Samuel Palmer, Megan Duster, Simone Warrack, April Zehm, Patricia Filas-Mortensen, Christopher Crnich

    Studies have shown that skilled nursing facilities (SNFs) are reservoirs for methicillin-resistant Staphylococcus aureus (MRSA). The extent to which resident-to-resident transmission accounts for the high burden of MRSA in these facilities remains poorly understood. The objective of this study was to estimate the frequency of intra-facility MRSA acquisition in a sample of SNFs participating in a longitduinal study in Wisconsin. MRSA colonization among a cohort of 449 subjects residing in six SNFs in Southern Wisconsin was measured using serial, multi-anatomical surveillance culturing. Phenotypic acquisitions events (i.e., MRSA [-] to MRSA[+]) were identified and further characterized both temporally (calendar date) and genetically (pulse-field gel electrophoresis). An intra-facility acquisition event was defined as incident recovery of an MRSA isolate that was genetically identical to at least one other strain previously recovered in a study facility. A Marascuilo procedure for comparing multiple proportions was employed to determine whether the proportion of intra-facility MRSA acquisitions differed across study facilities. Linear regression was employed to assess if certain facility-level characteristics were associated with rates of intra-facility MRSA acquisition. 129 acquisition events were identified that met our criteria, of which 74 were determined to be intra-facility (57.4%) [95% CI: 45.5–67.6%]. Statistically significant differences were found between the intra-facility acquisition proportion of multiple SNFs. A facility’s baseline MRSA prevalence was significantly associated with its intra-facility MRSA acquisition rate (R2 = 0.784, P-value = 0.012). Intra-facility acquisition represents a large proportion of the burden of MRSA observed in SNFs. The rate of intra-facility acquisition is variable between facilities but may, in part, be explained by the prevalent burden of MRSA in the facility (i.e., MRSA colonization pressure to characteristics of the facility). Whether other facility characteristics, including infection prevention practices are contributing to these transmission dynamics requires further study. All authors: No reported disclosures.

  • Open Access

    Changes to the Composition of the Gastrointestinal Microbiome after Probiotics for Clostridium difficile Infection in Adults

    by Shoshannah Eggers, Travis De Wolfe, Anna Barker, Megan Duster, Kimberly Dill-McFarland, Garret Suen, Nasia Safdar

    Background: Clostridium difficile infections (CDI) in the US have markedly increased. Disturbances to the gastrointestinal (GI) microbiome due to antibiotic use predisposes patients to CDI. Probiotics are recommended to prevent GI microbiota changes during CDI antibiotic treatment, but efficacy is unknown. We conducted a randomized, double-blinded, placebo-controlled, examination of clinical and GI microbiota changes in subjects administered probiotics during a primary episode of CDI. Methods: 33 subjects with a primary episode of CDI were randomized to once daily oral probiotic, consisting of four different bacterial strains, or placebo for 4-weeks (week 0–4) concurrent to antibiotic treatment. Subjects completed a daily stool diary, and stool samples were collected at enrollment (week 0), at the end of the probiotic or placebo adjunct regimen (week 4), and 4 weeks post-treatment (week 8). DNA was extracted for 16S rRNA sequencing with Illumina MiSeq. Microbial diversity, richness, and community structure were compared using analysis of variance and permutational analysis of variance. Similarity percentage analysis identified the operational taxonomic units driving the variation in β diversity. Results: The duration of diarrhea (P = 0.039) and total days of diarrhea (P = 0.005) both decreased in the probiotic group compared with the placebo group. Analysis of community structure showed significant differences between treatment groups overall (P = 0.017) and in both groups over time (P = 0.007), but not between groups at each individual time point. Subjects in the probiotic group had a higher abundance of the family Lachnospiraceae at week 4 than subjects in the placebo group. By week 8 the abundance of Lachnospiraceae did not differ between subjects administered probiotic or placebo. Conclusion: Lack of difference in overall community structure between groups at each time point is likely due to concurrent antibiotic therapy. The differential abundance of Lachnospiraceae likely contributes to the differences in the diarrheal outcomes observed between groups, as it has previously been associated with attenuated C. difficile pathology. Shortening the duration of diarrhea from an initial CDI may reduce the spread of C. difficile and improve clinical outcomes. Disclosures: All authors: No reported disclosures.

  • On the hands of patients with Clostridium difficile: A study of spore prevalence and the effect of hand hygiene on C difficile removal

    by Anna K. Barker, Caroline Zellmer, Jessica Tischendorf, Megan Duster, Susan Valentine, Marc Oliver Wright, Nasia Safdar


  • A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO)

    by Anna K Barker, Megan Duster, Susan Valentine, Timothy Hess, Laurie Archbald-Pannone, Richard Guerrant, Nasia Safdar

    Clostridium difficile is the most common cause of hospital-acquired infections, responsible for >450000 infections annually in the USA. Probiotics provide a promising, well-tolerated adjunct therapy to standard C. difficile infection (CDI) treatment regimens, but there is a paucity of data regarding their effectiveness for the treatment of an initial CDI. We conducted a pilot randomized controlled trial of 33 participants from February 2013 to February 2015 to determine the feasibility and health outcomes of adjunct probiotic use in patients with an initial mild to moderate CDI. The intervention was a 28 day, once-daily course of a four-strain oral probiotic capsule containing Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07 and B. lactis Bl-04. The control placebo was identical in taste and appearance. Registered at clinicaltrials.gov: trial registration number = NCT01680874. Probiotic adjunct therapy was associated with a significant improvement in diarrhoea outcomes. The primary duration of diarrhoea outcome (0.0 versus 1.0 days; P = 0.039) and two exploratory outcomes, total diarrhoea days (3.5 versus 12.0 days; P = 0.005) and rate of diarrhoea (0.1 versus 0.3 days of diarrhoea/stool diary days submitted; P = 0.009), all decreased in participants with probiotic use compared with placebo. There was no significant difference in the rate of CDI recurrence or functional improvement over time between treatment groups. Probiotics are a promising adjunct therapy for treatment of an initial CDI and should be further explored in a larger randomized controlled trial.


  • Chemical Genomics, Structure Elucidation, and in Vivo Studies of the Marine-Derived Anticlostridial Ecteinamycin

    by Thomas P. Wyche, René F. Ramos Alvarenga, Jeff S. Piotrowski, Megan N. Duster, Simone R. Warrack, Gabriel Cornilescu, Travis J. De Wolfe, Yanpeng Hou, Doug R. Braun, Gregory A. Ellis, et al.

    A polyether antibiotic, ecteinamycin (1), was isolated from a marine Actinomadura sp., cultivated from the ascidian Ecteinascidia turbinata. 13C enrichment, high resolution NMR spectroscopy, and molecular modeling enabled elucidation of the structure of 1, which was validated on the basis of comparisons with its recently reported crystal structure. Importantly, ecteinamycin demonstrated potent activity against the toxigenic strain of Clostridium difficile NAP1/B1/027 (MIC = 59 ng/μL), as well as other toxigenic and nontoxigenic C. difficile isolates both in vitro and in vivo. Additionally, chemical genomics studies using Escherichia coli barcoded deletion mutants led to the identification of sensitive mutants such as trkA and kdpD involved in potassium cation transport and homeostasis supporting a mechanistic proposal that ecteinamycin acts as an ionophore antibiotic. This is the first antibacterial agent whose mechanism of action has been studied using E. coli chemical genomics. On the basis of these data, we propose ecteinamycin as an ionophore antibiotic that causes C. difficile detoxification and cell death via potassium transport dysregulation.


  • Open Access

    Serratia marcescensBacteremia: Nosocomial Cluster Following Narcotic Diversion

    by Leah M. Schuppener, Aurora E. Pop-Vicas, Erin G. Brooks, Megan N. Duster, Christopher J. Crnich, Alana K. Sterkel, Aaron P. Webb, Nasia Safdar

    OBJECTIVE: To describe the investigation and control of a cluster ofSerratia marcescensbacteremia in a 505-bed tertiary-care center.METHODS: Cluster cases were defined as all patients withS. marcescensbacteremia between March 2 and April 7, 2014, who were found to have identical or related blood isolates determined by molecular typing with pulsed-field gel electrophoresis. Cases were compared using bivariate analysis with controls admitted at the same time and to the same service as the cases, in a 4:1 ratio.RESULTS: In total, 6 patients developedS. marcescensbacteremia within 48 hours after admission within the above period. Of these, 5 patients had identicalSerratiaisolates determined by molecular typing, and were included in a case-control study. Exposure to the post-anesthesia care unit was a risk factor identified in bivariate analysis. Evidence of tampered opioid-containing syringes on several hospital units was discovered soon after the initial cluster case presented, and a full narcotic diversion investigation was conducted. A nurse working in the post-anesthesia care unit was identified as the employee responsible for the drug diversion and was epidemiologically linked to all 5 patients in the cluster. No further cases were identified once the implicated employee’s job was terminated.CONCLUSION: Illicit drug use by healthcare workers remains an important mechanism for the development of bloodstream infections in hospitalized patients. Active mechanisms and systems should remain in place to prevent, detect, and control narcotic drug diversions and associated patient harm in the healthcare setting.Infect Control Hosp Epidemiol2017;38:1027–1031


  • Risk of Clostridium difficile Infection in Hematology-Oncology Patients Colonized With Toxigenic C. difficile

    by Cara M. Cannon, Jackson S. Musuuza, Anna K. Barker, Megan Duster, Mark B. Juckett, Aurora E. Pop-Vicas, Nasia Safdar

    : The prevalence of colonization with toxigenic Clostridium difficile among patients with hematological malignancies and/or bone marrow transplant at admission to a 566-bed academic medical care center was 9.3%, and 13.3% of colonized patients developed symptomatic disease during hospitalization. This population may benefit from targeted C. difficile infection control interventions. Infect Control Hosp Epidemiol 2017;38:718–720